In fact, impaired CD95 signaling has been implicated in many pediatric haemopoietic malignancies, including childhood acute leukemias (ALL and AML) and B-cell non-Hodgkin lymphomas (NHLs) [29,30,31]. This evidence concerns the gene FAS and B-cell non-Hodgkin lymphoma.